Eleva is advancing its proprietary, moss-expressed Factor H (CPV-104) program into clinical development (CTA filing achieved in Q4/2024) with an initial focus on C3 Glomerulopathy (C3G). Our compound has the potential to restore the natural balance in the complement system, thereby controlling over-activation while retaining its protective properties. Beyond C3G, the program has shown therapeutic potential in a range of indications including atypical hemolytic uremic syndrome (aHUS) and the dry form of age-related macular degeneration (dry AMD).